242 34. Milosevic J, et al. Emerging role of LRRK2 in human neural progenitor cell cycle progression, survival and differentiation. Mol neurodegener. 2009;4:25. 35. Lin X, et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson’s-disease-related mutant alpha-synuclein. Neuron. 2009;64:807–27. 36. Betarbet R, Sherer TB, Greenamyre JT. Animal models of Parkinson's disease. Bioessays. 2002;24:308–18. 37. Ng CH, et al. Parkin protects against LRRK2 G2019S mutant- induced dopaminergic neurodegeneration in Drosophila. J Neuro- sci. 2009;29:11257–62. 38. Paisan-Ruiz C, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron. 2004;44:595– 600. 39. Schüle B, Reijo Pera RA, Langston JW. Can cellular models revolutionize drug discovery in Parkinson's disease? Biochim Bio- phys Acta. 2009;1792:1043–51. 40. Wakabayashi K, Takahashi H, Ohama E, Ikuta F. Parkinson’s disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol. 1990; 79:581–3. 41. Zimprich A, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601–7. 42. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegenera- tion: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101–12. 43. Masliah E, et al. Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science. 2000;287:1265. 44. van der Putten H, et al. Neuropathology in mice expressing human α-synuclein. J Neurosci. 2000;20:6021–9. 45. Kahle PJ, et al. Subcellular localization of wild-type and Parkinson’s disease-associated mutant α-synuclein in human and transgenic mouse brain. J Neurosci. 2000;20:6365–73. 46. Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal fea- tures of Parkinson’s disease. Nat Neurosci. 2009;12:826–8. 47. Marti MJ, Tolosa E, Campdelacreu J. Clinical overview of the synucleinopathies. Mov Disord. 2003;18 Suppl 6:S21–7. 48. Kirik D, et al. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson’s disease. Proc Natl Acad Sci USA. 2003;100:2884–9. 49. Maries E, Dass B, Collier TJ, Kordower JH, Steece-Collier K. The role of alpha-synuclein in Parkinson’s disease: insights from animal models. Nat Rev Neurosci. 2003;4:727–38. 50. Takahashi K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861–72. 51. Yu J, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917–20. 52. Paisan-Ruiz C, et al. LRRK2 gene in Parkinson disease: mutation analysis and case control association study. Neurology. 2005;65: 696–700. 53. Hernandez D, et al. The dardarin G 2019 S mutation is a common cause of Parkinson’s disease but not other neurodegenerative diseases. Neurosci lett. 2005;389:137–9. Curr Neurol Neurosci Rep (2012) 12:237–242 54. Nichols WC, et al. Genetic screening for a single common LRRK2 mutation in familial Parkinson’s disease. Lancet. 2005;365:410–2. 55. Kachergus J, et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a com- mon founder across European populations. Am J Hum Genet. 2005;76:672–80. 56. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord. 2009;24:2175–86. 57. Ibanez P, et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson’s disease. Lancet. 2004;364: 1169–71. 58. Waters CH, Miller CA. Autosomal dominant Lewy body parkin- sonism in a four-generation family. Ann Neurol. 1994;35:59–64. 59. Park IH, et al. Disease-specific induced pluripotent stem cells. Cell. 2008;134:877–86. 60. Soldner F, et al. Parkinson’s disease patient-derived induced plu- ripotent stem cells free of viral reprogramming factors. Cell. 2009;136:964–77. 61. Israel MA, et al. Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells. Nature 2012, 482:216–220. In this recent study, scientists have created stem cell–derived, in vitro models of sporadic and hereditary AD, using iPSCs from patients with the neurodegenerative disorder. Their finding suggests that sporadic AD patients may have genomes that generate strong neuronal phenotypes. Therefore, future iPSC stud- ies have the potential to provide great insight into the underlying mechanisms behind the observed heterogeneity in sporadic neuro- degenerative disease pathogenesis. 62. Byers B, et al. SNCA triplication Parkinson’s patient’s iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress. PLoS One 2011, 6:e26159. Scientistis succeeded in the gener- ation of iPSC-derived mDA neurons from a patient with a triplication in the α-synuclein gene (SNCA). These iPSCs readily differentiated into functional neurons and exhibited cardinal disease-related pheno- types in culture. These phenotypes include the accumulation of α- synuclein, inherent overexpression of markers of oxidative stress, and sensitivity to peroxide-induced oxidative stress. These findings show that the SNCA-triplication mutation can affect cellular function in culture and corroborate a cell autonomous etiology for PD that is independent of complex entirety of the diseased brain. 63. Nguyen HN, et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 2011, 8:267–280. Scientists successfully derived DA neurons from iPSCs carrying a G2019S point mutation in LRKK2. These neurons exhibited increased expression of key oxidative stress- response genes and α-synuclein protein; they are also more sensitive to caspase-3 activation and cell death caused by exposure to stress agents, such as hydrogen peroxide, MG-132, and 6- hydroxydopamine, than wild-type DA neurons. This observed height- ened stress sensitivity is consistent with existing understanding of early PD phenotypes and presents a potential therapeutic target. 64. Dimos JT, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008;321:1218–21. 65. Ebert AD, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature. 2009;457:277–80.